v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 6 Months Ended
Sep. 26, 2026
Sep. 27, 2025
Cash Flows from Operating Activities:    
Net income $ 79,315 $ 72,715
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 54,871 57,013
Amortization of fair value inventory step-up 0 4,491
Share-based compensation expense 19,539 16,901
Impairment of intangible assets 0 8,584
Deferred income taxes 3,234 (3,956)
Other non-cash operating activities 5,389 2,361
Change in operating assets and liabilities:    
Change in accounts receivable (8,064) (3,702)
Change in inventories 978 25,058
Change in prepaid income taxes 2,428 3,136
Change in other assets and other liabilities (18,277) (23,688)
Change in accounts payable and accrued expenses 41,010 (30,197)
Net cash provided by operating activities 180,423 128,716
Cash Flows from Investing Activities:    
Capital expenditures (22,677) (8,770)
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment (15,657) (29,149)
Proceeds from sale of property, plant and equipment 813 417
Other investments (9,000) (25,966)
Net cash used in investing activities (46,521) (63,468)
Cash Flows from Financing Activities:    
Payments on revolving credit facility 100,000 0
Repayment of term loan borrowings (3,125) (3,125)
Share repurchases 0 (75,000)
Contingent consideration payments (17,597) 0
Proceeds from employee stock purchase plan 3,123 3,476
Proceeds from exercise of stock options 2,377 525
Cash used to net share settle employee equity awards (3,888) (4,795)
Other financing activities (29) (75)
Net cash used in financing activities (119,139) (78,994)
Effect of exchange rates on cash and cash equivalents 509 3,409
Net Change in Cash and Cash Equivalents 15,272 (10,337)
Cash and Cash Equivalents at Beginning of Period 245,440 306,763
Cash and Cash Equivalents at End of Period $ 260,712 $ 296,426